Consolidated figures · ₹ crore
| ₹ Cr | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| 5,514 | 6,367 | 7,106 | 8,184 | 11,174 | 14,756 | 15,262 | 16,927 | |
| COGS | 1,897 | 2,052 | 2,209 | 2,718 | 3,663 | 4,898 | 5,198 | 5,691 |
| Gross profit | 3,618 | 4,315 | 4,897 | 5,466 | 7,511 | 9,858 | 10,064 | 11,236 |
| 2,223 | 2,741 | 3,314 | 3,702 | 5,166 | 6,643 | 6,898 | 7,781 | |
| 1,395 | 1,574 | 1,583 | 1,763 | 2,345 | 3,215 | 3,166 | 3,455 | |
| OPM % | 25.3% | 24.7% | 22.3% | 21.6% | 21% | 21.8% | 20.8% | 20.4% |
| Depreciation | 448 | 552 | 715 | 814 | 1,113 | 1,569 | 1,687 | 1,957 |
| Interest | 71 | 65 | 58 | 68 | 419 | 974 | 897 | 990 |
| 339 | 229 | 257 | 102 | 85 | 854 | 1,305 | -60 | |
| Profit before tax | 1,215 | 1,186 | 1,068 | 983 | 897 | 1,525 | 1,887 | 448 |
| Tax | 212 | 315 | 222 | 212 | 254 | 227 | 457 | 79 |
| Tax % | 17.5% | 26.6% | 20.8% | 21.5% | 28.3% | 14.9% | 24.2% | 17.7% |
| 1,003 | 871 | 846 | 772 | 643 | 1,298 | 1,429 | 369 | |
| PAT margin % | 18.2% | 13.7% | 11.9% | 9.4% | 5.8% | 8.8% | 9.4% | 2.2% |
| EPS (₹) | 15.3 | 6.3 | 6.2 | 5.4 | 3.9 | 8.6 | 8.5 | 2.8 |
| EPS adjusted (₹) | 7.5 | 6.2 | 6.2 | 5.4 | 3.9 | 8.5 | 8.4 | 2.4 |
| 3.3% | 0% | 0% | 9.2% | 38.7% | 5.8% | 5.9% | 17.7% | |
| Annual report | Annual report for Mar 2019 | Annual report for Mar 2020 | Annual report for Mar 2021 | Annual report for Mar 2022 | Annual report for Mar 2023 | Annual report for Mar 2024 | Annual report for Mar 2025 | Annual report for Mar 2026 |
| ₹ Cr | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 100 | 100 | 0 | 300 | 600 | 600 | 600 | 600 | 600 | 600 | 811 |
| Reserves | 3,171 | 3,934 | 2 | 4,881 | — | 7,027 | 7,832 | 17,267 | 19,183 | 21,044 | 33,221 |
| Minority interest | — | — | — | — | — | 881 | 1,038 | 4,622 | 5,491 | 6,069 | 2,590 |
| 1,031 | — | — | — | — | 3,556 | 4,904 | 17,771 | 15,730 | 17,756 | 14,825 | |
| 2,074 | 4,424 | 0 | 4,809 | — | 6,459 | 6,020 | 11,783 | 15,066 | 13,329 | 12,204 | |
| Total equity & liabilities | 6,375 | 8,458 | 2 | 9,990 | — | 18,522 | 20,394 | 52,043 | 56,071 | 58,797 | 63,651 |
| — | — | — | — | 5,945 | 6,364 | 6,569 | 29,468 | 30,644 | 31,963 | 36,486 | |
| CWIP | — | — | — | — | — | 2,254 | 3,420 | 2,588 | 3,985 | 4,102 | 4,613 |
| Investments | 230 | 26 | -3 | 64 | — | 1,952 | 1,588 | 2,069 | 1,000 | 1,127 | 1,779 |
| 6,145 | 8,432 | 5 | 9,926 | — | 7,953 | 8,817 | 17,919 | 20,442 | 21,605 | 20,773 | |
| Total assets | 6,375 | 8,458 | 2 | 9,990 | — | 18,522 | 20,394 | 52,043 | 56,071 | 58,797 | 63,651 |
As reported in NSE results XBRL. Segment result is before tax and finance costs. ROCE uses that annual result divided by segment assets less liabilities.
Latest reported period · 31 Mar 2026 · ₹ crore
| Segment | Revenue | Result | Assets | Liabilities | Capital employed | ROCE % |
|---|---|---|---|---|---|---|
| Biosimilars | 10,431.2 | 587.6 | 47,888.1 | 21,178.9 | 26,709.2 | 2.2 |
| CRDMO | 3,738.7 | 487.5 |
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| 1,160 | 1,177 | 1,853 | 2,954 | 4,061 | 1,994 | |
| -3,625 | -1,699 | -14,282 | -1,005 | -234 | -2,082 | |
| 2,564 | 242 | 13,049 | -2,333 | -1,854 | -924 | |
| Net cash flow | 99 | -280 | 619 | -383 | 1,973 | -1,012 |
| Free cash flow | -357 | -521 | 257 | 1,273 | 1,925 | 196 |
| CFO / Operating profit % | 70.2% | 59.7% | 73.8% | 89.6% | 128.3% | 57.7% |
| 7,054.9 |
| 2,214.7 |
| 4,840.2 |
| 10.07 |
| Generics | 3,168.1 | -134.8 | 8,992.6 | 3,756.1 | 5,236.5 | -2.57 |
₹ crore by fiscal year